AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating Huntington's disease, a rare neurodegenerative condition. This designation ...

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...

A drug originally developed for high blood pressure could find a new use in the treatment of Huntington's disease, thanks to an artificial intelligence-based drug discovery programme at Spain's ...

Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial. Pridopidine is an oral agonist of the S1R protein ...

A survey conducted in Canada examined the prevalence of perceived genetic discrimination against patients with Huntington disease. The respondents reported discrimination not only by insurance or ...

THE WEEK’S MOST POPULAR SONGS RANKED BY COUNTRY RADIO AIRPLAY AUDIENCE IMPRESSIONS, AS MEASURED BY MEDIABASE AND PROVIDED BY LUMINATE. Morgan Wallen Last week Weeks at no. 1 Weeks on chart M.C ...

Apr. 21, 2025 — A new way to deliver disease-fighting proteins throughout the brain may improve the treatment of Alzheimer's disease and other neurological ... Integrative Approach Reveals ...

Apr. 23, 2025 — New multidisciplinary research shows that the brain forms memories of cold experiences and uses them to control our metabolism. The study shows that cold memories form in the ...

Having a new pump that can continuously provide small doses of his medication for Parkinson's disease smooths out the cycle of ups and downs taking pills once imposed on his life. "At night ...